Cargando…

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients

BACKGROUND: The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor. METHOD: We designed a real-world study to investigate using patients’ clinical and genetic aberrations to forecast the prognoses of BCBM patients. We recruited 146 BCBM pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Ning, Tian, Can, Wu, Hui, Yang, Xiaohong, liu, Liping, Li, Jing, Xiao, Huawu, Gao, Jianxiang, Lu, Jun, Hu, Xuming, Cao, Min, Shui, Zhengrong, Tang, Yu, Wang, Xiao, Yang, Jianbo, Hu, Zhe-Yu, Ouyang, Quchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243401/ https://www.ncbi.nlm.nih.gov/pubmed/32499836 http://dx.doi.org/10.1177/1758835920915305

Ejemplares similares

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
por: Liu, Binliang, et al.
Publicado: (2023)

Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance
por: Hu, Zhe-Yu, et al.
Publicado: (2018)

PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies
por: Tang, Yu, et al.
Publicado: (2020)

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study
por: Tian, Can, et al.
Publicado: (2022)

Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database
por: Xie, Ning, et al.
Publicado: (2022)

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
por: Hu, Zhe-Yu, et al.
Publicado: (2023)

Corrigendum to “FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients”
Publicado: (2021)

HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report
por: OUYANG, QUCHANG, et al.
Publicado: (2016)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
por: Zhou, Dabo, et al.
Publicado: (2019)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Corrigendum to “Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer” [Translational Oncology (2019) 12, 764–774]
por: Zhou, Dabo, et al.
Publicado: (2021)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
por: Zhou, Zhen, et al.
Publicado: (2021)

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study
por: Xie, Ning, et al.
Publicado: (2022)

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
por: Tang, Yu, et al.
Publicado: (2022)

FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
por: Wang, Yue, et al.
Publicado: (2021)

Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
por: Kelam, Nela, et al.
Publicado: (2022)

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
por: Brown, Lauren M., et al.
Publicado: (2023)

The Aberrant Expression of the Mesenchymal Variant of FGFR2 in the Epithelial Context Inhibits Autophagy
por: Nanni, Monica, et al.
Publicado: (2019)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma
por: Sun, Zhen, et al.
Publicado: (2020)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
por: Formisano, Luigi, et al.
Publicado: (2019)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation
por: Kong, Yuan, et al.
Publicado: (2017)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
por: Kim, Young Saing, et al.
Publicado: (2018)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Aberrant Expression of Long Non-coding RNAs in Exosomes in Follicle Fluid From PCOS Patients
por: Wang, Liping, et al.
Publicado: (2021)

Genome-wide aberrant methylation in primary metastatic UM and their matched metastases
por: Smit, Kyra N., et al.
Publicado: (2022)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy
por: Chen, Hai‐Long, et al.
Publicado: (2018)

Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
por: Zhou, Wen-Ya, et al.
Publicado: (2016)

Novel FGFR1 Variants Are Associated with Congenital Scoliosis
por: Wang, Shengru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cu7q3r928ctibksh1er7cnstog